Petros Pharmaceuticals (NASDAQ:PTPI) versus Kyntra Bio (NASDAQ:KYNB) Head to Head Review

Petros Pharmaceuticals (NASDAQ:PTPI) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Risk & Volatility

Petros Pharmaceuticals has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Institutional & Insider Ownership

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 12.2% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Petros Pharmaceuticals and Kyntra Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Kyntra Bio	2,199.13%	N/A	-36.71%

Analyst Ratings

This is a breakdown of current ratings for Petros Pharmaceuticals and Kyntra Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0	0	0	0	0.00
Kyntra Bio	1	1	2	1	2.60

Kyntra Bio has a consensus price target of $32.50, indicating a potential upside of 382.91%. Given Kyntra Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Petros Pharmaceuticals.

Valuation & Earnings

This table compares Petros Pharmaceuticals and Kyntra Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11 million	0.02	-$8.16 million	($1.64)	-0.00
Kyntra Bio	$6.44 million	4.23	$183.45 million	$40.46	0.17

Kyntra Bio has higher revenue and earnings than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Kyntra Bio beats Petros Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.